Semaglutide Linked to Lower Fracture Rates Than Other Weight-Loss Medications in Large Study

A large population-based study found that semaglutide, a GLP-1 receptor agonist used for weight loss, was associated with a lower risk of fractures compared to other weight-loss medications, according to findings published in a peer-reviewed medical journal and reported by Medscape Medical News on June 16, 2026. The study challenges earlier concerns that weight loss medications might accelerate bone loss and increase fracture risk, offering new insights for clinicians managing patients on these drugs.

The research, conducted over a three-year period with over 100,000 participants, showed that individuals using semaglutide experienced a 20% lower fracture rate than those using alternative weight-loss medications, including phentermine and orlistat. The findings were consistent across age groups and body mass indices, though the study did not establish causation. "This is a significant observation," said Dr. Emily Carter, an endocrinologist at Harvard Medical School, who was not involved in the study. "It suggests that semaglutide may have a more favorable bone health profile than previously assumed, but further research is needed to understand the mechanisms behind this effect."

Previous clinical trials had raised concerns about GLP-1 receptor agonists and bone health, with some studies reporting reduced bone mineral density in patients taking these drugs. However, the new population-based analysis—published in The Journal of Bone and Mineral Research—found no evidence of increased fracture risk with semaglutide. Instead, the data suggested a protective effect, particularly in postmenopausal women, where fracture rates were 28% lower among semaglutide users compared to non-users.

The study’s lead author, Dr. Rajesh Patel of the University of California, San Francisco, emphasized that the results should not be interpreted as a blanket endorsement of semaglutide for bone health. "We cannot conclude that semaglutide prevents fractures," Patel stated. "This is an observational finding that warrants further investigation in controlled trials." The researchers noted that semaglutide’s impact on bone metabolism remains poorly understood, and the study did not account for lifestyle factors such as diet and exercise, which also influence fracture risk.

For patients already taking semaglutide, the findings may offer reassurance, but experts caution against altering treatment plans based on a single study. The American Society for Bone and Mineral Research (ASBMR) issued a statement urging clinicians to maintain current fracture prevention strategies, including calcium and vitamin D supplementation, weight-bearing exercise, and regular bone density monitoring. "While these results are intriguing, they do not change clinical practice guidelines," said ASBMR president Dr. Michael Rosenblatt. "Patients should continue following evidence-based recommendations for bone health."

The study’s limitations include its observational design, which cannot prove causation, and the lack of long-term data on semaglutide’s effects beyond three years. Additionally, the analysis did not compare semaglutide to other GLP-1 agonists like liraglutide or dulaglutide, leaving questions about whether the fracture risk reduction is specific to semaglutide or a class effect. Researchers are now planning a randomized controlled trial to investigate the mechanisms behind the observed association, with preliminary results expected in 2027.

For now, the findings add another layer to the complex relationship between weight-loss medications and skeletal health. While semaglutide may pose a lower fracture risk than some alternatives, its long-term impact on bone density and fracture prevention remains an open question. Clinicians are advised to weigh these new data against established fracture risk factors, including age, sex, and prior history of osteoporosis, when managing patients on weight-loss therapies.

Why does this study matter?
The research contradicts earlier warnings about GLP-1 drugs and bone loss, which had led some clinicians to recommend against their use in patients with osteoporosis. Before this study, a 2023 meta-analysis in The Lancet Diabetes & Endocrinology found that GLP-1 agonists were associated with a modest increase in bone turnover markers, raising concerns about potential bone weakening. However, the new population-based data suggest that semaglutide may not follow the same pattern, at least in terms of fracture outcomes. This discrepancy highlights the need for more research into how different weight-loss medications interact with skeletal health.

What happens next?
The study’s authors are collaborating with the National Institutes of Health (NIH) to design a prospective trial comparing semaglutide, liraglutide, and lifestyle interventions for fracture risk in overweight and obese adults. The trial, expected to enroll 5,000 participants, will also assess changes in bone mineral density and muscle mass over five years. In the meantime, regulatory agencies like the FDA and EMA are reviewing the findings, though no immediate changes to drug labeling are expected. Patients considering semaglutide for weight loss should discuss the potential benefits and risks with their healthcare provider, particularly if they have preexisting bone health concerns.

How do the findings compare to other weight-loss drugs?
The study’s fracture risk reduction with semaglutide stands in contrast to data on other weight-loss medications. For example, orlistat—a lipase inhibitor—has been linked to higher rates of vitamin D deficiency and potential bone mineral density loss, though clinical fracture data is limited. Meanwhile, phentermine, a stimulant-based appetite suppressant, has not been closely studied for skeletal effects, but its use is often limited to short-term therapy due to cardiovascular risks. The new findings suggest semaglutide may offer a more favorable bone health profile than these alternatives, though further head-to-head trials are needed to confirm this.

What remains uncertain?
The study does not explain why semaglutide might reduce fracture risk. Possible mechanisms include its effects on appetite regulation (leading to slower, more sustainable weight loss), indirect benefits from improved glucose metabolism, or even unintended interactions with bone metabolism pathways. Some researchers speculate that semaglutide’s impact on gut hormones, such as GLP-2, could play a role, but this remains speculative. Until a mechanistic study clarifies these pathways, clinicians should interpret the findings cautiously.

Key takeaways for patients and clinicians

• Semaglutide was associated with a 20% lower fracture rate in this large population study, challenging earlier concerns about GLP-1 drugs and bone health.
• The findings are observational and do not prove causation; further trials are needed before changing clinical guidelines.
• Patients on semaglutide should continue standard fracture prevention measures, including calcium, vitamin D, and weight-bearing exercise.
• The study does not compare semaglutide to other GLP-1 agonists like liraglutide or dulaglutide, leaving questions about class-wide effects.
• Clinicians should individualize treatment decisions, considering a patient’s overall fracture risk profile rather than relying solely on this study’s results.

Sources and further reading

• Medscape Medical News (June 16, 2026): "Semaglutide Linked to Fewer Fractures"
• The Journal of Bone and Mineral Research (2026): "Population-Based Analysis of Fracture Risk in Users of Semaglutide vs. Other Weight-Loss Medications"
• American Society for Bone and Mineral Research (ASBMR) statement (June 2026)
• NIH clinical trial registration (expected 2027): "GLP-1 Agonists and Skeletal Health in Overweight Adults"